The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke in Patients With Cryptogenic Stroke and High Risk PFO

TerminatedOBSERVATIONAL
Enrollment

582

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
StrokePFO - Patent Foramen Ovale
Interventions
DEVICE

Occlutech PFO Occluder

The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.

Trial Locations (17)

Unknown

St. Paul's Hospital, Vancouver

CHU Clermont-Ferrand, Clermont-Ferrand

Institut de Cardiologie,groupe hospitalier pitié salpêtrière, Paris

New Civil Hospital, Strasbourg

CHU Rangueil, Toulouse

Charité Universität Berlin, Berlin

Herzzentrum Bremen, Bremen

Klinikum Coburg, Coburg

Herzzentrum der Universität zu Köln, Cologne

Herzzentrum Dresden Universitätsklinik an der Technischen Universität Dresden, Dresden

Universitätsklinikum Düsseldorf, Düsseldorf

CardioVasculäres Centrum Frankfurt, Frankfurt

Uniklinik Freiburg, Freiburg im Breisgau

Asklepios Klinik Hamburg, Hamburg

Uniklinik Heidelberg, Heidelberg

University Jena, Jena

Centro Cardiologico Monzino, Milan

Sponsors
All Listed Sponsors
lead

Occlutech International AB

INDUSTRY